MDxHealth is trading 40.77% down at $0.36 after suspending full-year 2026 revenue guidance of $110–115 million; preliminary Q3 revenue was approximately $22.7 million, flat year over year.
- Management said Q3 revenue fell short of expectations and cited unexpected sales-force turnover after Resolve mdx was discontinued.
- Tissue-based test volume fell 11%; full Q3 results are scheduled for November 12.
- Live trading volume was not provided.